Wall Street’s SHOCK 150% Bet! Should YOU Buy This 1 Stock NOW?
Did you know Wall Street analysts are screaming "yes" to buying Viking Therapeutics stock, predicting a staggering 150% return on the dip? This incredible optimism largely hinges on their lead weight-loss drug candidate, VK2735, which has shown promising phase 2 efficacy data and is being developed with a unique dual formulation. However, caution is warranted as some questionable tolerability data emerged from oral trials, and crucial phase 3 results are still years away, not expected until late 2027 or 2028. Surprisingly, despite the analyst hype, even The Motley Fool Stock Advisor team did not include Viking Therapeutics among its top 10 current buys. Weighing these dramatic possibilities requires careful consideration, so make sure to subscribe to our channel for more crucial insights before making your next move.
Tags/Hashtags: #vktx #stock #investing #vk2735 #pharmaceuticals #biotech #nvidia
Leave a Reply